WHO refreshes the global map of antimicrobial resistance threats
The WHO Bacterial Priority Pathogens List 2024 recasts the global hierarchy of antibiotic-resistant bacteria at a moment when the bacterial treatment pipeline remains strained. Using a multicriteria decision analysis framework, investigators scored 24 resistant pathogens across eight dimensions: mortality, non-fatal burden, incidence, 10-year resistance trends, preventability, transmissibility, treatability, and antibacterial pipeline status. The exercise was not a simple tally of deaths or hospitalizations. It combined epidemiology, clinical severity, spread potential, and the practical reality of whether new drugs are actually available or likely to arrive soon.
Carbapenem-resistant Klebsiella pneumoniae emerged at the top of the ranking with a total score of 84%, while penicillin-resistant group B streptococci fell to the bottom at 28%. That spread signals how sharply the clinical and public health threat varies across bacterial species and resistance mechanisms. A resistant organism can be devastating not only because it kills, but because it concentrates in settings where treatment options are already thin, transmission is efficient, and empiric therapy often fails before susceptibility data return.
Among the organisms placed in the highest quartile were antibiotic-resistant Gram-negative bacteria, including Klebsiella pneumoniae, Acinetobacter spp, and Escherichia coli, along with rifampicin-resistant Mycobacterium tuberculosis. This grouping reflects a familiar and stubborn clinical pattern: Gram-negative organisms remain disproportionately difficult to control because of intrinsic resistance mechanisms, rapid acquisition of additional resistance determinants, and limited therapeutic redundancy. When rifampicin resistance enters tuberculosis care, the result is especially consequential because resistance compromises one of the backbone agents in a disease that already requires prolonged treatment and coordinated public health follow-up.
Community pathogens rose alongside hospital superbugs
The list also gives substantial weight to pathogens that move well outside tertiary hospitals. Fluoroquinolone-resistant Salmonella enterica serotype Typhi ranked at 72%, Shigella spp at 70%, and Neisseria gonorrhoeae at 64%. These are not abstract laboratory concerns. They are organisms that circulate through communities, schools, households, sexual networks, food systems, and travel corridors, creating repeated opportunities for transmission and repeated pressure on first-line antibiotics.
A resistant enteric pathogen changes the bedside conversation in a very direct way. Empiric therapy that once worked reliably may fail, diarrhea becomes harder to contain, and the downstream burden falls not only on individual patients but on outbreaks, contact tracing, and antimicrobial stewardship programs. For gonorrhea, the stakes are similar: resistance narrows treatment choices while ongoing transmission keeps the organism in circulation, forcing public health systems to balance cure, prevention, and surveillance at the same time.
Pseudomonas aeruginosa and Staphylococcus aureus also remained important entries on the final list. Their inclusion is unsurprising, but it is clinically meaningful because both organisms are deeply embedded in routine inpatient care, surgical prophylaxis, intensive care practice, and device-associated infection management. Resistance in either organism can turn a common infection into a prolonged admission, an escalation to broader-spectrum agents, or a difficult source-control problem.
Expert agreement was high and the ranking held steady
The preferences survey included 100 international experts, with 79 responses and 78 completed surveys. The resulting agreement was strong: Spearman’s rank correlation coefficient and Kendall’s coefficient of concordance were both 0.9. In practical terms, that level of agreement suggests that the ranking did not depend on a narrow slice of opinion or one region’s experience. The subanalyses, including clustering by experts’ background and geographic origin, did not produce substantial shifts in the final ordering.
This stability matters because pathogen prioritization often invites debate over whether burden, resistance, or feasibility should dominate the final ranking. Here, the decision framework appears to have held together across viewpoints. The scoring system did not erase uncertainty, but it did produce a reproducible hierarchy that can support funding decisions, surveillance planning, and target selection for antibacterial research.
The process also reflects an important policy tension. Some organisms rank highly because they already cause a large burden and are resistant in ways that make routine care harder. Others may not dominate global incidence yet still merit attention because transmissibility, resistance trajectory, and poor treatability combine to create outsized future risk. Multicriteria scoring is one of the few tools capable of holding those realities in the same frame.
The list points to more than drug discovery
The interpretation is narrower than a wish list for new antibiotics. It is a demand for sustained investment across multiple fronts. Novel antibacterials remain necessary, especially for the Gram-negative pathogens and rifampicin-resistant Mycobacterium tuberculosis that continue to sit near the top of the hierarchy. The current pipeline, however, is not enough on its own to erase the threat. The ranking itself makes clear that access to existing drugs, vaccine coverage, and infection prevention and control must move in parallel.
Equitable access to effective treatment remains a central issue because a drug that exists on paper but does not reach patients in time has limited public health value. Vaccine coverage can reduce the incidence of infections that would otherwise drive antibiotic use and selection pressure. Infection prevention and control remains the quiet infrastructure behind resistance control: hand hygiene, isolation when needed, environmental cleaning, antimicrobial stewardship, and surveillance all shape how quickly resistant strains move through wards and communities.
The 2024 WHO list therefore functions as both a scientific ranking and a strategic warning. It names the organisms that most urgently deserve attention, but it also exposes the structural weakness of relying on antibiotics alone to contain AMR. The list was developed by the WHO AMR Division with support from grants from the Government of Austria, the Government of Germany, the Government of Saudi Arabia, and the European Commission’s Health Emergency Preparedness and Response Authority. The next test is whether research funders, ministries of health, and hospital systems treat the ranking as a planning tool rather than a static catalogue of familiar threats.